Axatilimab Biosimilar - Research Grade

Human

CSF1R

>1mg/ml

IgG4 - kappa

CHO Cells

Cabiralizumab Biosimilar - Research Grade (ICH5419), Emactuzumab Biosimilar - Research Grade (ICH5518)

https://www.imgt.org/mAb-DB/

ICH3002

P07333

1436

Blue ice

This product is a research-grade biosimilar of axatilimab, supplied as an unconjugated, non-therapeutic analog of the originator antibody for research use only. It reproduces the antigen-binding specificity of axatilimab, a human IgG4-kappa monoclonal antibody directed against the human colony-stimulating factor 1 receptor (CSF1R, UniProt P07333), and is intended as a tool reagent rather than as a clinical drug. Axatilimab blocks CSF1R signaling to modulate the survival, differentiation, and function of monocytes, macrophages, and related myeloid populations, and the clinical originator has been developed in the setting of chronic graft-versus-host disease and other fibrotic and inflammatory conditions. The biosimilar is offered at research grade with low endotoxin (<1 EU/mg), in bulk milligram-to-gram quantities suitable for functional and comparative studies. Because it is built around the CSF1R target rather than defined by a hybridoma clone, it is best used to interrogate CSF1R-dependent biology, to serve as a binding or neutralization reference standard, and as an isotype-matched human IgG4 tool in in-vitro assay development. CSF1R (colony-stimulating factor 1 receptor, also called CD115 or c-FMS; UniProt P07333) is a type III receptor tyrosine kinase expressed predominantly on cells of the mononuclear phagocyte lineage, including monocytes, macrophages, osteoclasts, microglia, and dendritic cell subsets. It is activated by two ligands, CSF1 (M-CSF) and IL-34, which drive receptor dimerization, autophosphorylation, and downstream signaling through PI3K-AKT, ERK, and other pathways that govern myeloid cell proliferation, survival, differentiation, and effector function. CSF1R signaling is central to tissue macrophage homeostasis and to the recruitment and polarization of macrophages in inflammation, fibrosis, and the tumor microenvironment. Blocking the ligand-binding region of CSF1R depletes or reprograms pathogenic macrophage populations, which underlies interest in CSF1R-directed antibodies for fibrotic, inflammatory, and oncologic indications.

CSF-1 receptor, M-CSF-R, Proto-oncogene c-Fms, Macrophage colony-stimulating factor 1 receptor, FMS

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Axatilimab (anti-CSF1R) Biosimilar

Q: Is the Axatilimab biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Axatilimab biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Axatilimab biosimilar target?

A: It is an unconjugated, non-therapeutic research analog of Axatilimab that binds CSF1R; for research use only.